secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001213900-24-069622
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies reports Q2 2024 net operating loss of $1.557M; IPO raises $6.4M post-quarter
--------------------------------------------------------------------------------

- Q2 2024 net operating loss $1.557M vs $2.505M in Q2 2023; EPS loss $0.26 on 5.991M shares.
- IPO on July 31, 2024 raised $6.4M gross with no warrants; all preferred shares and debt converted to equity.
- Post-IPO shares outstanding: 20.85M common shares, with 1.86M tradable; 18.99M under 6-month lockup.
- Lead program OST-HER2 Phase 2b osteosarcoma trial final results expected Q4 2024; interim data from 39/41 patients.
- Cash runway extended to mid-2025 based on IPO proceeds; company reports no debt post-IPO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390024069622/0001213900-24-069622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390024069622/ea0211542-8k_ostherap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-069622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer